Literature DB >> 22632372

Prevention of Graves' ophthalmopathy.

Luigi Bartalena1.   

Abstract

Smoking is the most important risk factor for the occurrence/progression of Graves' ophthalmopathy (GO), as well as for its lower/slower response to immunosuppression. Accordingly, refrain from smoking should be urged, both as primary prevention (removal of risk factors in Graves' patients without GO), secondary prevention (early detection and treatment of asymptomatic/very mild GO) and tertiary prevention (reduction of complications/disability of overt GO). A 6-month course of 200 μg/day sodium selenite can prevent progression of mild GO to more severe GO and is, therefore, a form of secondary prevention and, probably, primary prevention. Correction of thyroid dysfunction and stable maintenance of euthyroidism are important preventive measures. The optimal treatment for hyperthyroidism in patients with GO is uncertain, because evidence demonstrating the superiority of antithyroid drugs over thyroid ablation (radioiodine, thyroidectomy, or both) is lacking. If radioiodine is used, low-dose steroid prophylaxis is recommended, particularly in smokers, to prevent radioiodine-associated GO progression.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22632372     DOI: 10.1016/j.beem.2011.09.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  12 in total

Review 1.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

Review 2.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

3.  Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated Ophthalmopathy: A Randomized Clinical Trial.

Authors:  Yuan Pan; Yu-Xi Chen; Jian Zhang; Miao-Li Lin; Guang-Ming Liu; Xue-Liang Xu; Xian-Qun Fan; Yong Zhong; Qing Li; Si-Ming Ai; Wen Xu; Jia Tan; Hui-Fang Zhou; Dong-Dong Xu; Hui-Ying Zhang; Bei Xu; Sha Wang; Jun-Jie Ma; Shuo Zhang; Lin-Yang Gan; Jian-Tao Cui; Li Li; Yan-Yan Xie; Xinxing Guo; Nathan Pan-Doh; Zhuo-Ting Zhu; Yao Lu; Yu-Xun Shi; Yi-Wen Xia; Zuo-Yi Li; Dan Liang
Journal:  JAMA Ophthalmol       Date:  2022-09-29       Impact factor: 8.253

Review 4.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

Review 5.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

6.  Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  Eur Thyroid J       Date:  2020-07-13

7.  Marine-Lenhart syndrome with papillary thyroid carcinoma.

Authors:  Hulusi Atmaca; Ramis Çolak; Zihni Acar Yazici; Mehmet Kefeli; Fevziye Canbaz Tosun
Journal:  J Res Med Sci       Date:  2015-04       Impact factor: 1.852

8.  Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves' orbitopathy and analysis on who requires additional therapy.

Authors:  Theodora Tsirouki; Alexandra Bargiota; Stelios Tigas; Agathi Vasileiou; Eftichia Kapsalaki; Zoe Giotaki; Ioannis Asproudis; Agathokles Tsatsoulis; Georgios Koukoulis; Evangelia E Tsironi
Journal:  Clin Ophthalmol       Date:  2016-11-17

Review 9.  Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.

Authors:  Giulia Lanzolla; Guia Vannucchi; Ilaria Ionni; Irene Campi; Federica Sileo; Elisa Lazzaroni; Michele Marinò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-22       Impact factor: 5.555

10.  Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.

Authors:  Hui-Chuan Kau; Shi-Bei Wu; Chieh-Chih Tsai; Catherine Jui-Ling Liu; Yau-Huei Wei
Journal:  Oxid Med Cell Longev       Date:  2016-06-02       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.